share_log
Breakings ·  Dec 19, 2024 20:00
Nurix Therapeutics Receives U.S. FDA Fast Track Designation for Nx-5948 for the Treatment of Relapsed or Refractory Waldenstrom’s Macroglobulinemia
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment